Created by: Rheil De Guzman
Date Created: May 18, 2024
Last Modified: May 18, 2024 by
Innovestor Life Science
- Investment Thesis: Focused on building and investing in clinically meaningful opportunities in
biopharmaceuticals, medical devices and related areas.
- Most Recent Fund: Teralys Capital Innovation Fund 2023
- Investment Strategy: Biopharmaceuticals & Healthcare
- Investment Criteria:
- Emphasis on disruptive technologies.
- Scalability.
- Strong management teams.
- Investment Stage: From early-stage start-ups to growth and expansion.
- Average Investment Size:
- Target geographics: Canada and the United States.
- Total # of Investments: Over 230.
- Total # of Portfolio Companies: Over 230.
- Relevant Biotech/Health Portfolio Companies:
- General Observations: Focus on fostering innovation in the life sciences and technology
sectors by creating, building, advising and investing in businesses in biopharmaceuticals,
healthcare and the innovation sector in general.
- Mimetogen Pharmaceuticals - Is a Phase III clinical stage biotechnology
company focused on developing the use of peptidomimetics as a novel approach
to treating ophthalmic diseases with high unmet medical needs.
- BaroSense, Inc. - is a medical device compan, that focuses on the research and
development of innovative, minimally invasive medical devices for the treatment
of obesity.
- Milestone Pharmaceuticals, Inc. - Aims to provide a sense of security to patients
with PSVT and other episodic cardiovascular conditions through its
investigational therapies.
- Resonant Medical - Develops, manufactures and commercializes 3D ultrasound
image-guided adaptive radiotherapy products.
-
Cedric Bisson
Partner at Teralys Capital
Montreal, Quebec, Canada
LinkedIn
Executive Summary:
- Entrepreneur and Investor that focuses on life sciences and healthcare investments, as well as
growth opportunities. His specialized expertise and network in life sciences contribute greatly to
the execution of Teralys' investment strategy in this sector.
- Expert in creating, building, advising and investing in businesses in biopharmaceuticals,
healthcare and the innovation sector in general.
- M.D. degree from McGill University and a J.D. (law) degree from Université de Montréal.
Current Role:
- Partner at Teralys Capital (2011 - Present)
- Focuses on life sciences and healthcare investments.
- Leads growth and expansion opportunities within the firm.
Board Member/Observer:
- Mimetogen Pharmaceuticals (Jan 2006 - Present) - Is a Phase III clinical stage biotechnology
company focused on developing the use of peptidomimetics as a novel approach to treating
ophthalmic diseases with high unmet medical needs.
- PROCURE ALLIANCE (2009 - Present) – is Quebec's largest charity fighting prostate cancer by
means of education and awareness programs for men and their families, as well as the financing
of research leveraging a proprietary world-class Biobank of biological materials and data to
accelerate the discovery and development of new cures against prostate cancer.
- Board Member and Investment Committee Member at Grand Challenges Canada (Mar 2013 -
Present) – supports integrate science and technology, social and business innovation.
Previous Roles:
- Committee Member, Accel-Rx - Canada's Health Science Accelerator (2016-2020)
- Chairman, La Biennale de Montréal (2013 - 2018)
- Board Observer, BaroSense, Inc. (2009 - 2013)
- Board Member, Milestone Pharmaceuticals, Inc. (2006 - 2011)
- Managing Partner, iNovia Capital (2003 - 2011)
- Founder & Investment Committee Member, MSBi Valorisation (2003 - 2011)
- Board Member, Resonant Medical (2003 - 2010
- Associate Principal, McKinsey & Company (1997 - 2003)
Education:
- Bachelor of Laws (LL.B.) - Université de Montréal (1991 – 1994)
- Medicine (M.D.) - McGill University (1986 – 1991)
- Diploma of Collegiate Studies - College Jean-de-Brebeuf
